Korean College of Rheumatology Biologics and Targeted Therapy Registry

Sponsor
Seoul National University Hospital
Study ID
NCT01965132
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Biologic or targeted synthetic DMARD — DRUG

Study Details

We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients receiving biologics or targeted synthetic DMARDs. As this registry is to observe the "real world" use of anti-rheumatic treatments under routine clinical practice, no hypothesis to prove is planned.

Key Dates

First listed
Oct 18, 2013
Start date
Dec 1, 2012
Status verified
Apr 2024
Primary completion
Dec 31, 2029
Completion
Jun 30, 2030

Study Design

Enrollment
10,000 participants (estimated)

Arms

  • Arm: Biologic or targeted synthetic DMARD
    Korean patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis who will initiate, restart or switch to a biologic agent (etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab, ixekizumab, or biolsimilars) or a targeted synthetic DMARD

Primary Outcome Measure

Number of participants with adverse events during the use of biologics or targeted synthetic DMARDs in Korean patients with Rheumatic diseases [ Time Frame: up to 10 years ]

Central Contacts

Find similar trials

Nationwide
Psoriatic arthritis trialsRheumatoid arthritis trialsRheumatology trialsAutoimmune disease trialsMusculoskeletal disorders trials

Related Studies